MV012 968

Drug Profile

MV012 968

Alternative Names: OE4 (RSV-A2-dNS1-dNS2-DSH-dGm)-Gsnull-line19F; Respiratory syncytial virus vaccine - Meissa Vaccine; RSV vaccine - Meissa Vaccine

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 12 Jul 2017 Preclinical trials in Respiratory syncytial virus infections (Prevention) in USA (Parenteral)
  • 12 Jul 2017 Meissa Vaccines receives NIH SBIR grant from National Institutes of Health for MV 012 968 development in Respiratory Syncytial virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top